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Despite excellent survival of marrow transplantation (BMT) in
acquired severe aplastic anemia (SAA) using sibling donors, graft-
versus-host disease (GVHD) continues to remain a major problem
resulting in long-term complications and impaired quality of life.
Between Aug 1989 and Aug 2004, 35 patients at our centre with
acquired SAA underwent BMT from HLA-identical sibling donors
using cyclophosphamide (CY) 50 mg/kg  4 (days 5 to 2) and
anti-CD52 MoAb 0.75–1 mg/kg BW as conditioning. Prior to
1999, rat derived anti-CD52 MoAb (Campath-1G) was used. We
switched to humanised version of anti-CD52 MoAb (Alemtu-
zumab) when it became available in 1999. Median age at BMT was
17 yrs (range 4–46). Prior to BMT, 58% were heavily transfused
(50 transfusions) and 42% had previously failed ATG. Unma-
nipulated bone marrow was used as source of stem cells in all
except one. GVHD prophylaxis was with cyclosporine (CSA) alone
in 21 (60%) patients; 14 received anti-CD52 MoAb in addition to
CSA. Eight patients had graft failure (primary, 4; secondary, 4)
with a cumulative incidence of 23%. Graft failure was non-signif-
icantly higher in those receiving CSA and anti-CD52 MoAb as
GVHD prophylaxis. No cases of graft failure are seen in 10 pa-
tients treated after 1999. The cumulative incidence of acute grade
II-IV GVHD and chronic GVHD was 13% and 4%, respectively.
None developed extensive chronic GVHD. Of the 19 recipients
positive for cytomegalovirus (CMV), reactivation was seen in 5
(26%) with in 100 days. No cases of late CMV reactivation were
observed. Six patients died of complications related to BMT at a
median of 248 days (range 47–414). With a median follow-up of 59
months, the 5-year survival was 83% (95% C.I. 68–96). There was
a non-signiﬁcant trend towards improved survival in patients trans-
planted after 1995 (94% vs. 74%). Of the 29 survivors, serial
chimerism studies were available on 20 and showed: 100% donor
cells, 15; stable mixed chimerism with 85% donor cells, 3; and
autologous recovery, 2. All survivors are transfusion-independent
and have performance status of 100% except one who developed
avascular necrosis. We conclude that the conditioning regimen
containing CY and anti-CD52 MoAb is well tolerated and efﬁca-
cious for acquired SAA using HLA-matched sibling donors. Based
on the encouraging results of our study, further investigations are
in progress evaluating the role of Alemtuzumab in the transplant
protocols for AA using CSA alone as GVHD prophylaxis.
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IN VIVO SPATIAL AND TEMPORAL ANALYSES IN MICE REVEAL REDUN-
DANCY OF LYMPHOID TISSUES IN INDUCING ACUTE GVHD AFTER
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Beilhack, A.1; Schulz, S.1; Baker, J.1; Beilhack, G.F.1; Wieland, C.B.1;
Baker, E.M.1; Herman, E.I.1; Landan, G.1; Olson, J.A.1; Cao, Y.-A.2;
Contag, C.H.2; Negrin, R.S.2 1. Department of Medicine, Division of
BMT, Stanford University, Stanford, CA; 2. Department of Pediatrics,
Stanford University, Stanford, CA. (A.B. and S.S. contributed equally to
this work.)
Allogeneic hematopoietic cell transplantation is an effective ther-
apy for the treatment of malignant and non-malignant disorders,
and yet graft-versus-host disease (GVHD) remains a major obsta-
cle. Given the dynamic changes in immune cell subsets and tissue
organization, which occur in GVHD, localization and timing of
critical immunological events in vivo may reveal basic pathogenic
mechanisms of GVHD. We transplanted light-emitting luciferase
transgenic allogeneic splenocytes, and non-invasively monitored
their tissue distribution in living mice with major histocompatibil-
ity differences. Bioluminescence images were used to guide tissue
selection for high-resolution analyses of cell subsets and tissue
distribution. We demonstrated the sequential inﬁltration of lymph
nodes, Peyers patches and spleen by donor derived CD4 T cells
initially, followed by CD8 T cells, and an evolution of homing
receptors that correlated with patterns of cell distribution. These
data underline the important role of secondary lymphoid organs as
sites for GVHD initiation. To determine whether there are in-
structive priming sites for speciﬁc cell migration to GVHD target
organs such as gut, liver and skin we selectively interfered with the
migration of donor T cells to lymphoid organs by administration
of blocking antibodies to L-selectin and MAdCAM-1. Treated
allogeneic recipients interfered with entry of allogeneic splenocytes
into some secondary lymphoid tissues yet still developed GVHD.
Similarly, allogeneic Peyer’s patch deﬁcient recipients manifested
intestinal disease and succumbed to GVHD. These animals were
generated by treatment with lymphotoxin-alpha-IgG fusion pro-
tein during embryonic development. In vivo imaging and detailed
cellular analysis showed that remaining lymphoid tissues compen-
sated for the lack of others. Of importance, T cells that lacked
homing molecules for secondary lymphoid organs had alloreactive
properties in vitro, yet did not cause GVHD in vivo. Transplan-
tation of T cells with deﬁned homing properties therefore appears
to be a promising alternative in conferring protective immunity
early after HCT without the risk of GVHD.
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CHOOSING THE PATIENT FOR AMBULATORY STEM CELL TRANSPLAN-
TATION
Cantu-Rodriguez, O.G.; Gutierrez-Aguirre, C.H.; Gonzalez-LLano,
O.; Jaime-Perez, J.C.; Salazar-Riojas, R.; Martinez-Gonzalez, O.L.;
Gomez-Almaguer, D. Hospital Universitario Dr. Jose E. Gonzalez,
Monterrey, Nuevo Leon, Mexico.
Introduction: Allogeneic non-myeloablative stem cell transplan-
tation has been shown to reduce systemic toxicity and make pos-
sible the procedure in an ambulatory setting. Objective: To de-
scribe the characteristics of patients selected for an ambulatory
stem cell transplant based on a non-myeloablative chemotherapeu-
tic scheme. Material and Methods: Forty one patients were in-
cluded (26 males and 15 females) with the following diagnoses:
CML (12), CLL (2), ALL (5), AML (10), NHL (3), HL (1), MDS
(3), AA (2), MM (1) and renal cell adenocarcinoma (1). Ages ranged
between 8 and 61 years, with a mean of 36 years. Karnofsky scores
in all patients were superior to 80. All patients tolerated oral
feeding. Hemoglobin values ranged between 6.8 and 15.8 g/dl with
a mean of 12 g/dl. Platelet counts ranged between 14.4  109/L
and 1,200  109/L with a mean of 207.8  109/L. Serum creati-
nine ranged between 0.54 and 2 mg/dL with a mean of 0.9 mg/dL.
Results: Twenty patients completed the transplant on a fully
ambulatory setting basis. All had a Karnofsky scale value of 100.
Mean values were 13 g/dl (hemoglobin), 218.5  109/L (platelets)
and 0.9 g/dL (serum creatinine). Twenty-one patients began the
transplant procedure on an ambulatory basis, but eventually re-
quired admission because of fever and/or mucositis (inpatient days
ranged from 4 to 24 days). Karnofsky scores in these patients
ranged between 80 and 100. Mean values from these patients were
10.9 g/dl (hemoglobin), 195.7  109/L (platelets) and 0.93 mg/dL
(serum creatinine). Conclusions: Half of the patients admitted to
the study completed successfully their stem cell transplantation
procedure on an ambulatory setting. Factors related to this out-
come were normal hematological values after the transplant and
Karnofsky scores  80. These values could predict with a high
degree of probability whether or not a stem cell transplantation
could be successfully performed in an ambulatory setting.
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THE HEMATOPOIETIC CELL TRANSPLANTATION DATABASE AT DBMHC
Helmberg, W.1; Malkki, M.2; Feolo, M.1; Hoffman, D.1; Petersdorf, E.2
1. NCBI, Bethesda, MD; 2. Fred Hutchinson Cancer Research Institute,
Seattle, WA.
The dbMHC www.ncbi.nih.gov/mhc is a public resource for the
storage, display and analysis of MHC related genotype and clinical
data. This resource has been developed at National Center for
Bioinformatics (NCBI) through collaboration with the Interna-
tional Histocompatibility Working Group (IHWG). One module
provides public access to data of the Hematopoietic Cell Trans-
plantation project (HCT) of the IHWG. The HCT section of
dbMHC is intended to serve the unmet need of the research and
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clinical communities, for up-to-date data on matching and trans-
plant outcome. Only data with the explicit consent of the partici-
pating center have been entered into this database. All data have
been stripped of personal identiﬁers and links to submitting centers
in order to protect patient anonymity. All centers contributing to
this resource are listed on the main page of this project. Currently
updates of the data contained at this site are submitted via the
IHWG database. The HCT database currently contains data on
1551 unrelated donor transplants from 24 centers in 15 countries.
Data cover high resolution HLA typing for patient and donor of
HLA-A, B, C, DRB, DQB, DPB, diagnosis and stage at transplant,
patient and donor age and gender, survival and relapse. Transplant
pairs can be analyzed as deﬁned by the user. Data can be sorted,
viewed and downloaded by HLA allele or allele groups (i.e., HLA-
A*02), level of mismatch, and diagnosis. A special tool allows users
to interactively calculate, display, and download Kaplan Meier
Survival estimates for each user-deﬁned group of transplant pairs.
Download options of the data are available as individual data sets of
donor recipient pairs, as calculated data representing the outcome
of the Kaplan Meier estimate, or as images of Kaplan Meier
Curves. The database has been designed to include additional
genotyping data, e.g. KIR typing, SNPs, or microsatellites for each
donor-recipient pair. As data on additional genes becomes avail-
able, the database will be expanded to allow queries for combina-
tions of different genetic loci.
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THE IMPACT OF AGE AND OBESITY ON PLASMA BUSULFAN LEVELS
Im, E.K.; Cronin, S.; Levine, J.E.; Braun, T.; Yanik, G.; Reynolds, C.;
Uberti, J.P.; Ferrara, J.L.; Hutchinson, R.J. University of Michigan
Blood and Marrow Transplantation Program, Ann Arbor, MI.
IV busulfan is an alternative to oral busulfan in myeloablative
regimens prior to hematopoietic stem cell transplantation
(HSCT). Compared to oral busulfan which has variable bioavail-
ability, IV busulfan assures consistent drug delivery and may be
associated with a lower incidence of regimen-related toxicity. We
were interested in the effect of the type of body weight calculation
used for dosing busulfan on plasma busulfan levels. We investi-
gated the pharmacokinetic data from 58 sequential patients (age
7 m to 67 y) who received IV busulfan. In addition, the pharma-
cokinetic data for 11 patients who were obese or under weight who
received oral busulfan during the study period were also reviewed.
Patients received IV busulfan (0.8 mg/kg), or oral busulfan (1
mg/kg). Patients whose actual weight exceeded 140% of their ideal
body weight were dosed according to ideal [n12] or adjusted
[n29] body weight. The target Css range for all patients was
600–900 ng/ml. Plasma busulfan Css was measured at a single
reference laboratory by gas chromatography and mass spectrome-
try. Based on the pharmacokinetic result, remaining busulfan doses
were adjusted to achieve the desired Css target when averaged over
the 4-day dosing period. There was a signiﬁcant difference in mean
Css values between the IV and oral busulfan groups (727 ng/ml vs
986 ng/ml respectively) (p
0.001); furthermore there was less
variability in the Css for the IV group compared to the oral group
(p0.01). When IV busulfan patients were analyzed, a signiﬁcant
difference was observed among mean Css values of the actual,
ideal, and adjusted ideal body weight groups (658 ng/ml, 707
ng/ml, and 797 ng/ml) (p0.01). Consistent with other studies, we
found an inverse association between the age and busulfan clear-
ance in IV busulfan group (p0.004). In addition, 6/9 patients
between the age of 1 to 10 years had Css below the minimum
target. In this study, patients from 1 to 10 were all dosed by actual
body weight. In conclusion, use of IV busulfan produces a nar-
rower range of Css values. Both age and the choice of body weight
calculation for dosing impacts plasma busulfan levels. Consider-
ation should be given to increase dosing for children
10 years old.
Both adjusted and ideal body weight calculations led to Css values
in the target range. The use of ideal rather than adjusted ideal body
weight for dosing obese patients yielded Css values similar to that
achieved when using actual body weight for non-obese patients.
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BONE MARROW TRANSPLANTATION FOR DYSKERATOSIS CONGENITA:
ANALYSIS OF COMPLICATIONS AND LONG TERM FOLLOW-UP
Bonﬁm, C.M.S.; Bitencourt, M.A.; Funke, V.A.; Setubal, D.C.; Ruiz,
J.; Zanis-Neto, J.; deMedeiros, C.R.; Silva, R.L.F.; Pasquini, R. Bone
Marrow Transplantation Service Hospital de Clinicas UFPR, Curitiba,
PR, Brazil.
Introduction: DC is a rare bone marrow failure syndrome as-
sociated with aplastic anemia in approximately 50% of the cases.
It’s usually inherited in a X-linked manner and the diagnostic triad
includes reticulate hyper pigmentation, nail dystrophy and mucous
leukoplasia. Bone marrow transplantation (BMT) remains the only
potential curative treatment for these pts. Material and Methods:
Between 07/1993 and 07/2001, 5 pts with DC received an HLA
identical sibling BMT in our service. Sex M/F: 4/1. Median age at
BMT: 17 y (8–21).Median previous blood transfusions: 25 UI
(6–50 UI). All but one presented with nail dystrophy, abnormal
skin pigmentation and oral leukoplasia and had severe pancytope-
nia. Preparative regimen: Cyclophosphamide 200 mg/kg. GVHD
prophylaxis: Cyclosporine (csa)  methotrexate. Stem cell source:
bone marrow. TNC infused ranged from 2.2–5.13  108/kg (M:
2.27). Prophylactic antibiotics were given according to common
practice. Results: All pts are alive with a median follow up of 6
years (range: 3.2–11.2 y) and have full donor engraftment. Median
time to reach neutrophils 500/l was 27 days and platelets
20,000/l was 26 days after transplant. Two pts have a lower
platelet count (80,000/l) without any symptoms. Mucositis grade
II occurred in most pts. No pt developed acute or chronic GVHD,
VOD or autoimmune complications. Four pts developed eye com-
plications and two of them had to be submitted to eye surgery
(posterior uveitis and cornea transplantation for bilateral kerato-
conus). Only one pt complained of dry cough and progressive
dyspnea 10 years after transplant. He was evaluated at our BMT
Unit in 07/2004 when he presented with severe dyspnea and
hypoxemia (pO2: 61 mmHg). The chest CT showed diffuse inter-
stitial lesions and spirometry revealed a severe restrictive defect.
Echocardiogram was normal without pulmonary hypertension.
Pulmonary biopsy showed interstitial pulmonary ﬁbrosis with focal
areas of lymphocyte inﬁltrates. He was treated with steroids in
08/2004 and despite the very short follow up there is evidence of
clinical improvement (less fatigue and dyspnea and pO2: 89
mmHg). Conclusions: This preparatory regimen is safe and ef-
fective for the correction of the hematopoietic failure in pts with
DC, followed by a low complication rate. The mucocutaneous
abnormalities remain unchanged. Late pulmonary complications
occurred despite the absence of TBI in the preparative regimen.
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NK CELL ALLOREACTIVITY IS AN IMPORTANT MEDIATOR OF COSTIMU-
LATION-BLOCKADE-RESISTANT REJECTION DURING ALLOGENEIC
TRANSPLANTATION
Kean, L.S.1; Hamby, K.2; Coley, S.2; Lee, E.2; Adams, A.2; Pearson, T.2;
Larsen, C.2 1. Division of Hematology/Oncology/BMT, Department of
Pediatrics, and Department of Surgery, Atlanta, GA; 2. Department of
Surgery, Atlanta, GA.
Introduction: Immunologic tolerance remains an elusive goal of
clinical transplantation. Work in murine systems has demonstrated
that T-cell tolerance can be accomplished by providing T cells
with “signal 1” (alloantigen) while blocking “signal 2” through
costimulation blockade. We have used the costimulation blockade
reagents CTLA4-Ig and anti-CD40L in conjunction with nonmy-
eloablative bone marrow transplant to produce transplantation
tolerance in a fully MHC-mismatched murine system. However,
relatively large bone marrow doses (10  109/kg) must be used.
Costimulation-blockade-resistant rejection occurs when smaller
cell doses are transplanted. In this study, we investigated the
contribution of NK cell alloreactivity to this costimulation-block-
ade-resistant rejection response. Methods: We transplanted in-
creasing doses of Balb/C (NK1.1) bone marrow (0.5-, 2-, 5-, 10-,
and 20  106 cells) into C57BL/6 (NK1.1) mice after treatment
with 20 mg/kg busulfan. Costimulation-blockade with CTLA4-Ig
and anti-CD40L was given in the peritransplant period. Three
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